List of life sciences

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

U.S. News Unveils 2022-2023 Best Global Universities Rankings

Retrieved on: 
Tuesday, October 25, 2022

WASHINGTON, Oct. 25, 2022 /PRNewswire/ -- U.S. News & World Report, the global authority in education rankings, today published the 2022-2023 Best Global Universities rankings. The overall ranking in the new edition evaluates 2,000 schools – up from more than 1,700 last year – on academic research and reputation.

Key Points: 
  • The Best Global Universities rankings serve the broader U.S. News mission of providing trusted information and rankings such as Best High Schools , Best Colleges and Best Online Programs to help all students navigate their education options.
  • For more information on the Best Global Universities, visit Facebook and Twitter using #BestGlobal.
  • U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities.
  • Founded in 1933, U.S. News is headquartered in Washington, D.C.
    Clarivate is a global leader in providing solutions to accelerate the pace of innovation.

WCG FDAnews Announces: PDUFA and BsUFA Reauthorization Developments Webinar on Nov. 8, 2022

Retrieved on: 
Tuesday, October 25, 2022

FALLS CHURCH, Va., Oct. 25, 2022 /PRNewswire-PRWeb/ -- PDUFA and BsUFA Reauthorization Developments What Regulatory, Compliance, and Quality Professionals Need to Know Tuesday, Nov. 8, 2022, 1:30 p.m.–3:00 p.m. EST https://wcg.swoogo.com/pdufa-and-bsufa

Key Points: 
  • Former FDA official will provide the clarity you need in preparation for the PDUFA, BsUFA reauthorization changes.
  • After challenging debates, Congress passed a bare-bones reauthorization of the prescription drug and biosimilars user fee programs.
  • What does the future hold for the accelerated approval and clinical trial diversity drug- and biologic-related riders?
  • Now is the time to prepare for the inevitable changes.

3D Sensors Market Anticipated to Garner $57 Billion, Globally, By 2031 at 13% CAGR, Says Allied Market Research

Retrieved on: 
Monday, October 24, 2022

PORTLAND, Ore., Oct. 24, 2022 /PRNewswire/ -- Allied Market Research recently published a report, titled, "3D Sensor Market By Type (Image Sensor, Accelerometer Sensor, Position Sensor, Others), Technology (Structured Light, Time of Flight, Stereoscopic Vision, Ultrasound, Others), Connectivity (Wireless, Wired), End use (Consumer Electronics, Healthcare, Aerospace & Defense, Automotive, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031". As per the report, the global 3D sensor industry was pegged at $17.6 billion in 2021, and is expected to reach $57 billion by 2031, growing at a CAGR of 13% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario.

Key Points: 
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of " Market Research Reports "and "Business Intelligence Solutions."
  • AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
  • Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success.
  • Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

3D Sensors Market Anticipated to Garner $57 Billion, Globally, By 2031 at 13% CAGR, Says Allied Market Research

Retrieved on: 
Monday, October 24, 2022

PORTLAND, Ore., Oct. 24, 2022 /PRNewswire/ -- Allied Market Research recently published a report, titled, "3D Sensor Market By Type (Image Sensor, Accelerometer Sensor, Position Sensor, Others), Technology (Structured Light, Time of Flight, Stereoscopic Vision, Ultrasound, Others), Connectivity (Wireless, Wired), End use (Consumer Electronics, Healthcare, Aerospace & Defense, Automotive, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031". As per the report, the global 3D sensor industry was pegged at $17.6 billion in 2021, and is expected to reach $57 billion by 2031, growing at a CAGR of 13% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario.

Key Points: 
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of " Market Research Reports "and "Business Intelligence Solutions."
  • AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
  • Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success.
  • Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

AcuraBio Appoints Talented Senior Executives to Drive Global Growth Program

Retrieved on: 
Monday, October 17, 2022

AcuraBio brings two decades of experience in innovative therapeutics for customers in the biotech, pharmaceutical, and animal health industries.

Key Points: 
  • AcuraBio brings two decades of experience in innovative therapeutics for customers in the biotech, pharmaceutical, and animal health industries.
  • The CDMO provides recombinant proteins, vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics.
  • Dr. Haifer stated "These senior executive appointments are key to shaping the company as we move forward with our growth plans.
  • AcuraBio will immediately benefit from Guillaume Herry's experience with companies in the US, Europe and Australia designing and implementing growth strategies.

2CRSi SA: 2CRSi, Clever Cloud, Kalray and Vates join forces for Sovereign and Innovative Data Center Equipment

Retrieved on: 
Saturday, October 22, 2022

New classes of equipment are needed based on new hardware and software foundations to provide more efficient, power-optimized, and more open data center infrastructures.

Key Points: 
  • New classes of equipment are needed based on new hardware and software foundations to provide more efficient, power-optimized, and more open data center infrastructures.
  • The ReNESENS project is bringing together some of the most advanced French companies with unique expertise in the new class of DPU data processors, virtualization software, highly efficient servers and innovative data center architecture; Vates, Clever Cloud, Kalray and 2CRSi.
  • The project intends to develop an innovative and attractive sovereign proposition, for both end users and the ecosystem of data center players.
  • Clever Cloud will bring all its expertise to this initiative and to its partners 2CRSi, Kalray and Vates.

atai Life Sciences Announces R&D Day Agenda

Retrieved on: 
Thursday, October 20, 2022

NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day.

Key Points: 
  • NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day.
  • During this event, management and scientific leaders will provide a comprehensive review of atais diversified mental health pipeline.
  • atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.
  • atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland

Retrieved on: 
Tuesday, October 18, 2022

The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET).

Key Points: 
  • The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET).
  • Following the approval from FIMEA, Clairvoyant has launched the first of four planned trial sites in Finland.
  • In total, the clinical trial will be initiated in approximately 15 sites across Canada and Europe with the first site in Canada initiated in June of 2022.
  • Origin Therapeutics Holdings Inc. (the Company or Origin Therapeutics) is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector.